Novo Nordisk AS (OCSE:NOVO B)
kr 757.3 9.7 (1.3%) Market Cap: 3.36 Til Enterprise Value: 3.35 Til PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 97/100

Novo Nordisk A/S at UBS Global Healthcare Conference (Virtual) Transcript

May 20, 2020 / 01:10PM GMT
Release Date Price: kr223.75 (+0.70%)
Michael Leuchten
UBS Investment Bank, Research Division - Co-Head of Pharmaceuticals Research of Equity Research

Good morning, good afternoon, everybody. Welcome to this session. We have Kristoffer Berg with us from Novo Nordisk. We will go through 10, 15 minutes of prepared remarks, and we will then go into Q&A. If you have questions, you can submit them. We will see them on the screen, or I will see them on the screen. I can field them that way. And if there aren't any, then I will go ahead and ask questions myself.

Without further ado, Kristoffer, over to you.

Kristoffer Due Berg;S;Director of IR;North America
Novo Nordisk A

/--

Thank you very much, Michael. And thank you, everybody, for the interest in Novo Nordisk and for dialing in today. It's, obviously, a different way to conduct a conference, but, I guess, this is the new world we all have to adapt to, and so are we at Novo Nordisk.

And as you probably saw, we released our Q1 financial results 2 weeks ago. And they were, obviously

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot